Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

Inclusion Criteria:

1. Able to understand and willing to comply with all study requirements and proceduresthroughout the duration of the study and give written informed consent;
2. Aged ≥18 years;
3. Patients receiving moderate- or high-intensity statin therapy must meet one of thefollowing criteria¹ unless they have any exceptional conditions (see inclusioncriterion 4):
4. Aged ≥21 years with clinical atherosclerotic cardiovascular disease (ASCVD) (history of acute coronary syndrome or myocardial infarction, stable or unstableangina, coronary or other arterial revascularization, stroke, transient ischemicattack (TIA) presumed to be of atherosclerotic origin, or peripheral arterialdisease or revascularization), on a high-intensity statin (or moderate-intensitystatin if not a candidate for high-intensity statin due to safety concerns);
5. Aged ≥21 years with a history of LDL-C ≥190 mg/dL, which is not due to secondarymodifiable causes, on a high-intensity statin (or moderate-intensity statin ifnot a candidate for high-intensity statin due to safety concerns);
6. Aged 40 to 75 years, inclusive, without clinical ASCVD but with diabetes and ahistory of LDL-C of 70 to 189 mg/dL, inclusive, on a moderate- or high-intensitystatin; or
7. Aged 40 to 75 years, inclusive, without clinical ASCVD or diabetes, with ahistory of LDL-C of 70 to 189 mg/dL, inclusive, with estimated 10-year risk forASCVD of ≥7.5% by the Pooled Cohort Equation on a moderate- or high-intensitystatin;
8. Patients currently on a low-intensity statin or not on a statin, must meet one of thefollowing criteria:
9. Patient does not meet any criteria for moderate- or high-intensity statin therapylisted above (see inclusion criteria, criterion 3.a. through 3.d.);
10. Patient does meet one or more criteria for moderate- or high-intensity statintherapy listed above (see inclusion criteria 3.a. through 3.d.); but the patientis not a candidate for moderate or high-intensity statin due to safety concerns,or due to partial or complete statin intolerance; or
11. Patient does meet one or more criteria for moderate- or high intensity statintherapy listed above (see inclusion criteria 3.b. through 3.d., except for 3.a.);but the patient is not a candidate for moderate or high-intensity statin forprimary prevention after considering individual risk evaluation (e.g. current LDLC ≤70mg/dL) and patient preference;

Exclusion Criteria:

1. Patients who will require lipid-altering treatments other than study drugs (K-877 orfenofibrate), statins, ezetimibe, or PCSK9 inhibitors during the course of the study.These include bile acid sequestrants, non-study fibrates, niacin (>100 mg/day),omega-3 fatty acids (>1000 mg/day), or any supplements used to alter lipid metabolismincluding, but not limited to, red rice yeast supplements, garlic supplements, soyisoflavone supplements, sterol/stanol products, or policosanols;
2. Body mass index (BMI) >45 kg/m2 at Visit 1 (Week -8 or Week -6);
3. Patients with type 1 diabetes mellitus;
4. Patients with newly diagnosed (within 3 months prior to Visit 2 [Week -2]) or poorlycontrolled type 2 diabetes mellitus (T2DM), defined as hemoglobin A1c >9.5% at Visit 1 (Week -8 or Week -6);